These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19846140)

  • 41. Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.
    Hayashi A; Morikawa T; Kawai T; Kume H; Ishikawa S; Homma Y; Fukayama M
    Virchows Arch; 2014 Apr; 464(4):463-71. PubMed ID: 24446035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
    Cho KS; Oh HY; Lee EJ; Hong SJ
    Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma.
    Sudo T; Utsunomiya T; Mimori K; Nagahara H; Ogawa K; Inoue H; Wakiyama S; Fujita H; Shirouzu K; Mori M
    Br J Cancer; 2005 May; 92(9):1754-8. PubMed ID: 15856046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of target antigens in specific immunotherapy for renal cell carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    J Urol; 2007 Mar; 177(3):1157-62. PubMed ID: 17296437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
    Chen Y; Lin MC; Yao H; Wang H; Zhang AQ; Yu J; Hui CK; Lau GK; He ML; Sung J; Kung HF
    Hepatology; 2007 Jul; 46(1):200-8. PubMed ID: 17596871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osteopontin promotes EZH2 expression and tumor progression in nasopharyngeal carcinoma.
    Ma R; Luo X; Feng S; Li J; Fan Y; Wen W; Li H
    ORL J Otorhinolaryngol Relat Spec; 2014; 76(5):273-81. PubMed ID: 25471249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
    Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
    J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma.
    Zhang Z; Li J; Zheng H; Yu C; Chen J; Liu Z; Li M; Zeng M; Zhou F; Song L
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2685-93. PubMed ID: 19755649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [EZH2 expression in human prostate cancer and its clinicopathologic significance].
    Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L
    Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
    Wang HR; Wang MH; Lian GY; Wu DG
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):99-102. PubMed ID: 25613619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
    Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
    World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
    Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
    J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EZH2 is essential for glioblastoma cancer stem cell maintenance.
    Suvà ML; Riggi N; Janiszewska M; Radovanovic I; Provero P; Stehle JC; Baumer K; Le Bitoux MA; Marino D; Cironi L; Marquez VE; Clément V; Stamenkovic I
    Cancer Res; 2009 Dec; 69(24):9211-8. PubMed ID: 19934320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
    Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
    In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
    Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
    Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.
    Ding L; Kleer CG
    Cancer Res; 2006 Oct; 66(19):9352-5. PubMed ID: 17018586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
    Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
    J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.
    Ding L; Erdmann C; Chinnaiyan AM; Merajver SD; Kleer CG
    Cancer Res; 2006 Apr; 66(8):4095-9. PubMed ID: 16618729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery.
    Li K; Chen MK; Situ J; Huang WT; Su ZL; He D; Gao X
    Chin Med J (Engl); 2013 Jan; 126(1):82-7. PubMed ID: 23286483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
    Zhou J; Roh JW; Bandyopadhyay S; Chen Z; Munkarah AR; Hussein Y; Alosh B; Jazaerly T; Hayek K; Semaan A; Sood AK; Ali-Fehmi R
    Gynecol Oncol; 2013 Feb; 128(2):344-8. PubMed ID: 22871469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.